

## CLINICAL PROFILE AND OUTCOME OF 6 PATIENTS WITH BIOTINIDASEDEFICIENCY: AN EXPERIENCE FROM A TERTIARY CARE HOSPITAL OF PAKISTAN

ICNC
2022


17th INTERNATIONAL CHILD
NEUROLOGY CONGRESS
ANTALYA, TURKEY I OCTOBER 3-7, 2022


**Author: Dr. Iram Javed** 

## Background

Biotinidase deficiency (OMIM 253260) is an autosomal recessive metabolic disorder disorder in which the vitamin biotin is not recycled. Its estimated global incidence of 1:60,000 newborns. If untreated, affected individuals develop neurological and cutaneous symptoms. Untreated individuals with biotinidase deficiency either succumb to disease or are left with significant morbidity<sup>2</sup>. Most individuals with untreated biotinidase deficiency (BD) show progressive clinical features, including neurological abnormalities such as seizures, hypotonia, ataxia, developmental delay, sensorineural hearing impairment and optic atrophy. In Pakistan, patients with BD are almost never diagnosed early and often remain misdiagnosed.

We describe clinical course and follow-up of 6 children who presented in Paediatric Neurology department CH&ICH Faisalabad. These children were diagnosed on clinical basis and suggestive urinary organic acid profile. However Biotinidase enzyme level and BTD gene analysis could not be done due to non availability of facility in our area. All these cases responded dramatically to oral biotin within days to weeks. Biotinidase deficiency is reported in Pakistani children from different part of world, however; there are few such report from Pakistan. This highlights lack of awareness of biotinidase deficiency among physicians in Pakistan.





## Conclusion

The presently described cases also showed marked improvement following appropriate therapy except one case who expired due to poor compliance and follow up and one case with residual spastic dilplegia who was actually remained undiagnosed until 3.5 year when he presented to us.

Hence, Pakistani physicians need to be made aware of such a metabolic deficiencies which are both easily diagnosable and easily treatable to avoid long-term irreversible handicap.

## REFERENCES

- 1. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis 1991; 14:923-7
- 2. Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab 2011; 104:27-34.
- 3. Wolf B, Spencer R, Gleason T. Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. J Pediatr 2002; 140:242-6
- 4. Afroze, B., Wasay, M. (2013). Diagnosis, treatment and follow-Up in four children with biotinidase deficiency from Pakistan. Journal of the College of Physicians and Surgeons Pakistan, 23(11), 823-825.